Finoriq research workspace
INSMED Inc (INSM) SEC Filings & Filing Highlights
Insmed Incorporated develops and commercializes therapies for patients with serious and rare. Review INSM SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
- Company
- INSMED Inc (INSM)
- Ticker
- INSM
- Market Cap
- $23.3B
- Latest Price
- $107.73
- Industry
- Biotech & Pharma
INSMED Inc (INSM) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for INSMED Inc (INSM).
| Event | Form | Date |
|---|---|---|
| The annual meeting of shareholders of Insmed Incorporated (the “Company”) was held on May 13, 2...The annual meeting of shareholders of Insmed Incorporated (the “Company”) was held on May 13, 2026 (the “Annual Meeting”). Set forth below... | 8-K5.07 | 2026-05-15 |
| Insmed Reports First-Quarter 2026 Financial Results and Provides Business UpdateInsmed Reports First-Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-07 |
| Insmed Provides Clinical Update on Phase 2b CEDAR StudyInsmed Provides Clinical Update on Phase 2b CEDAR Study | 8-K8.01 | 2026-04-07 |
| Insmed Provides Clinical Update on Phase 2b CEDAR StudyInsmed Provides Clinical Update on Phase 2b CEDAR Study | 8-K7.01 | 2026-04-07 |
| Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® in Patients w...Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients wit... | 8-K8.01 | 2026-03-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.